LABStandard BioTools Inc.

$370M

Q3 2020 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$40M+50.4% YoY

Gross Profit

$25M63.5% margin

Operating Income

-$5M-13.7% margin

Net Income

-$6M-15.0% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+53.0%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$323M

Total Liabilities

$171M

Stockholders' Equity

$152M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40M	$26M	+50.4%
Gross Profit	$25M	$14M	+80.4%
Operating Income	-$5M	-$14M	+60.5%
Net Income	-$6M	-$13M	+53.4%

Revenue Segments

Product

$29M41%

Consumables

$17M24%

Instruments

$13M18%

Service

$6M9%

Collaboration Revenue

$3M5%

Product and Service, Other

$1M2%

Grant

$1M2%

Geographic Segments

Americas

$24M59%

EMEA

$9M22%

Asia Pacific

$7M18%

LAB Q3 2020 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena